170 related articles for article (PubMed ID: 27905500)
41. Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target.
Ravishankar S; Ambady A; Awasthy D; Mudugal NV; Menasinakai S; Jatheendranath S; Guptha S; Sharma S; Balakrishnan G; Nandishaiah R; Ramachandran V; Eyermann CJ; Reck F; Rudrapatna S; Sambandamurthy VK; Sharma UK
Tuberculosis (Edinb); 2015 Sep; 95(5):589-98. PubMed ID: 26073894
[TBL] [Abstract][Full Text] [Related]
42. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid.
Argyrou A; Vetting MW; Aladegbami B; Blanchard JS
Nat Struct Mol Biol; 2006 May; 13(5):408-13. PubMed ID: 16648861
[TBL] [Abstract][Full Text] [Related]
43. Cell Wall Associated Factors of Mycobacterium tuberculosis as Major Virulence Determinants: Current Perspectives in Drugs Discovery and Design.
Singh G; Kumar A; Maan P; Kaur J
Curr Drug Targets; 2017 Nov; 18(16):1904-1918. PubMed ID: 28699515
[TBL] [Abstract][Full Text] [Related]
44. Metabolically Specific
Zhong CJ; Hu XL; Yang XL; Gan HQ; Yan KC; Shu FT; Wei P; Gong T; Luo PF; James TD; Chen ZH; Zheng YJ; He XP; Xia ZF
ACS Appl Mater Interfaces; 2022 Sep; 14(35):39808-39818. PubMed ID: 36005548
[TBL] [Abstract][Full Text] [Related]
45. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
46. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex.
Rodrigues L; Machado D; Couto I; Amaral L; Viveiros M
Infect Genet Evol; 2012 Jun; 12(4):695-700. PubMed ID: 21871582
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of resistance of malaria parasites to antifolates.
Gregson A; Plowe CV
Pharmacol Rev; 2005 Mar; 57(1):117-45. PubMed ID: 15734729
[TBL] [Abstract][Full Text] [Related]
48. Production of P-aminobenzoic acid by metabolically engineered escherichia coli.
Koma D; Yamanaka H; Moriyoshi K; Sakai K; Masuda T; Sato Y; Toida K; Ohmoto T
Biosci Biotechnol Biochem; 2014; 78(2):350-7. PubMed ID: 25036692
[TBL] [Abstract][Full Text] [Related]
49. 8-Mercaptoguanine Derivatives as Inhibitors of Dihydropteroate Synthase.
Dennis ML; Lee MD; Harjani JR; Ahmed M; DeBono AJ; Pitcher NP; Wang ZC; Chhabra S; Barlow N; Rahmani R; Cleary B; Dolezal O; Hattarki M; Aurelio L; Shonberg J; Graham B; Peat TS; Baell JB; Swarbrick JD
Chemistry; 2018 Feb; 24(8):1922-1930. PubMed ID: 29171692
[TBL] [Abstract][Full Text] [Related]
50. Dihydropteroate synthase mutations in Pneumocystis jiroveci can affect sulfamethoxazole resistance in a Saccharomyces cerevisiae model.
Iliades P; Meshnick SR; Macreadie IG
Antimicrob Agents Chemother; 2004 Jul; 48(7):2617-23. PubMed ID: 15215118
[TBL] [Abstract][Full Text] [Related]
51. Dihydropteroate synthase from Streptococcus pneumoniae: characterization of substrate binding order and sulfonamide inhibition.
Vinnicombe HG; Derrick JP
Biochem Biophys Res Commun; 1999 May; 258(3):752-7. PubMed ID: 10329458
[TBL] [Abstract][Full Text] [Related]
52. Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs.
Viveiros M; Martins M; Rodrigues L; Machado D; Couto I; Ainsa J; Amaral L
Expert Rev Anti Infect Ther; 2012 Sep; 10(9):983-98. PubMed ID: 23106274
[TBL] [Abstract][Full Text] [Related]
53. Structural analysis of dihydrofolate reductases enables rationalization of antifolate binding affinities and suggests repurposing possibilities.
Bhosle A; Chandra N
FEBS J; 2016 Mar; 283(6):1139-67. PubMed ID: 26797763
[TBL] [Abstract][Full Text] [Related]
54. Phylogenetic and Structural Significance of Dihydrofolate Synthase (folC) Mutations in Drug-Resistant Mycobacterium tuberculosis.
Cheng VW; Leung KS; Kwok JS; Leung RK; Yang KY; Chan RC; Kam KM; Tsui SK
Microb Drug Resist; 2016 Oct; 22(7):545-551. PubMed ID: 27082669
[TBL] [Abstract][Full Text] [Related]
55. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
56. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
57. Virtual screening studies to identify novel inhibitors for Sigma F protein of Mycobacterium tuberculosis.
Mustyala KK; Malkhed V; Chittireddy VR; Vuruputuri U
Int J Mycobacteriol; 2015 Dec; 4(4):330-6. PubMed ID: 26964817
[TBL] [Abstract][Full Text] [Related]
58. [THE EFFECTIVENESS OF TREATMENT WITH COMBINED ISONIAZID AND PARA-AMINOSALICYLIC ACID (PAS) AND WITH ISONIAZID AND PARA-AMINOBENZOIC ACID (PABA) IN EXPERIMENTAL TUBERCULOSIS IN GUINEA PIGS].
VITOLO A
Riv Patol Clin; 1963 Oct; 18():621-8. PubMed ID: 14112642
[No Abstract] [Full Text] [Related]
59. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST
ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196
[TBL] [Abstract][Full Text] [Related]
60. Competition between H
Yu JF; Xu JT; Feng A; Qi BL; Gu J; Deng JY; Zhang XE
Antibiotics (Basel); 2023 Dec; 13(1):. PubMed ID: 38275323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
